Peripherally restricted GABA positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system

ABSTRACT

The present invention provides compounds and compositions which are positive allosteric modulators of GABA-A receptors that selectively target the peripheral nervous system and organs of the body, and which do not pass through the blood-brain barrier. The compounds and compositions of the present invention are useful for treatment of diseases or disorders which are mediated by GABA-A neuronal activity, such as, for example, visceral pain, gut motility, irritable bowel syndrome, functional abdominal pain, functional idiopathic diarrhea, inflammatory bowel diseases, drug induced pain, bile salt malabsorption, lactase or other carbohydrate intolerance.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a 35 U.S.C. § 371 U.S. national entry ofInternational Application PCT/US2015/037913, having an internationalfiling date of Jun. 26, 2015, which claims the benefit of U.S.Provisional Application No. 62/017,418, filed Jun. 26, 2014, the contentof each of the aforementioned applications is herein incorporated byreference in their entirety.

FIELD OF THE INVENTION

This invention relates to compounds which are positive allostericmodulators of GABA-A receptors that are peripherally restricted. Thecompounds of the present invention can be useful in the treatment ofsystemic diseases of the body which can be modulated by the use ofcompounds which are positive allosteric modulators of GABA-A receptorsthat are peripherally restricted. In some embodiments, the compounds ofthe present invention can be useful in the treatment of diseases such asirritable bowel syndrome. More specifically, the invention relates tocompounds and methods for the treatment of irritable bowel syndrome,where such compounds comprise pharmaceutically acceptable amounts of aperipherally-restricted GABA-A receptor positive allosteric modulator.

BACKGROUND OF THE INVENTION

This invention focuses on the development of compounds which arepositive allosteric modulators of GABA-A receptors that are peripherallyrestricted, and their use in the treatment of disease. In someembodiments, the compounds of the present invention are useful in thetreatment of irritable bowel syndrome (IBS), a disorder that is definedclinically by intermittent abdominal pain in association with alteredbowel movements in the absence of any other structural or inflammatorycause. Based on the dominant bowel pattern, IBS patients are clinicallyphenotyped into three categories: IBS-D (diarrhea predominant), IBS-C(constipation predominant), and IBS-M (mixed or alternating betweendiarrhea and constipation). IBS is a very common medical disorder with aprevalence estimated between 6-20% in most developed countries andassociated with significant impairment of quality of life andsocio-economic costs estimated in the billions of dollars every year.¹Unfortunately, there are few therapeutic options available for patients,with only two approved drugs (lubiprostone and linaclotide) that areboth secretagogues and indicated only for symptomatic relief of IBS-C.There are currently no approved prescription drugs for treatment ofIBS-D.

The pathogenesis of IBS-D (as with other forms of IBS) remains poorlyunderstood but is thought to be associated with hyperexcitability ofneurons, affecting both extrinsic (spinal) and intrinsic (enteric)nerves leading to chronic visceral hypersensitivity and alteredmotility, respectively. As compared with controls, patients with IBSshow increased colonic myoelectrical activity both at baseline and aftera meal.² Suppression of such excitability is therefore a logicaltherapeutic target. Most pharmacological approaches to the treatment ofIBS focus on the role of serotonin (5-HT), released from chemo- andmechanosensitive enterochromaffin cells residing in the mucosa, leadingto activation of nociceptive nerves as well as intrinsic primaryafferent neurons (IPANs) in the enteric nervous system (ENS) to initiatereflexes for motility and secretion.³ Unfortunately, 5-HT receptormodulators (e.g. tegaserod or alosetron) have only been modestlyeffective and associated with significant adverse effects leading totheir withdrawal from the general market. There is therefore a greatneed for alternative approaches.⁴

Gamma Aminobutyric Acid (GABA) is the most important inhibitoryneurotransmitter in the central nervous system (CNS). Activation ofneuronal GABA receptors results in hyperpolarization and stabilizationof neuronal excitability. GABA-ergic neurons are also abundant in theenteric nervous system and both GABA-A (inotropic) and GABA-B(metabotropic) receptors are present in the gut, mediating distinctfunctional effects.⁵⁻¹³ GABA-B receptor agonists have been investigatedfor treatment of IBS. ¹⁴

It is thought that the therapeutic benefit of brain penetrating GABA-Amodulating benzodiazepines, such as diazepam, in IBS resultspredominantly from the relief of anxiety that often accompanies IBS.¹⁷The use of brain penetrating benzodiazepines (or other brain penetratingcompounds), however, is clinically problematic both because of sedation,and the potential for addiction and physical dependence on chronic use.An alternate approach has been described for tofisopam and its isomer,dextofisopam which is currently under study for IBS. These moleculeshave been classified as atypical benzodiazepines which enter the CNS andbind to a novel binding site within the central nervous system that maybe responsible for mediating its actions.¹⁸ ¹⁹

GABA-A receptor positive allosteric modulators have heretofore beenconcerned with CNS conditions like anxiety, insomnia, and epilepsy notIBS.

SUMMARY OF THE INVENTION

The present invention provides compounds and compositions which arepositive allosteric modulators of GABA-A receptors that selectivelytarget the peripheral nervous system and organs of the body, and whichdo not pass through the blood-brain barrier. The compounds andcompositions of the present invention are useful for treatment ofdiseases or disorders which are mediated by GABA-A neuronal activity,such as, for example, visceral pain, gut motility, irritable bowelsyndrome, functional abdominal pain, functional idiopathic diarrhea,inflammatory bowel diseases, drug induced pain, bile salt malabsorption,lactase or other carbohydrate intolerance.

In an embodiment, the present invention provides compounds which areGABA-A receptor positive allosteric modulators that areperipherally-restricted to the GABAergic neurons of the body outside ofthe brain and central nervous system.

In accordance with an embodiment, the present invention provides acompound of formulas 1 and 2:

wherein, A₁, A₂, and A₃ are independently selected from C or N, where atleast one of A₁, A₂, or A₃ is a C unsubstituted or substituted with agroup consisting of alkyl, alkenyl, alkynyl, cycloalkyl,heterocycloalkyl, aryl, heteroaryl, —COOR₁₀, —COR₁₀), —NR₁₀R₁₁, and—CONR₁₀R₁₁;each of R₁₀ and R₁₁ is independently H, alkyl, alkenyl, alkynyl,cycloalkyl, heterocycloalkyl, aryl, or heteroaryl optionally substitutedwith one or more amidinyl, guanidinyl, phosphate, sulfate, tetrazole,3-hydroxyisoxazole, quaternary ammonium salts including urea, primaryamides, sulfonamides, sulfonyl ureas, acylamidines, acylguanidines, or—NR₁₂R₁₃ groups;each of R₁₂ and R₁₃ is independently H, —CONH₂, —SOONH₂, alkyl, alkenyl,alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;X is O;Y is selected from H, OH, OQ, and CO₂Q where Q is a prodrug thatliberates Y═H or Y═OH;Z is selected from oxygen and an electron lone pair;R₁ is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl,heteroaryl optionally substituted with one or more halo, CF₃, CN, NO₂,COOH, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₁₋₄ alkynyl, OH, OR (where OR is C₁₋₄alkyl or C₁₋₄ fluoroalkyl), SO₂R (where R is C₁₋₄ alkyl or C₁₋₄fluoroalkyl);R₅ is selected from the group consisting of aryl, heteroaryl, orcycloalkenyl groups optionally substituted with one or more halo, CF₃,CN, NO₂, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₁₋₄ alkynyl, OH, OR (where OR isC₁₋₄ alkyl or C₁₋₄ fluoroalkyl), and SO₂R (where R is C₁₋₄ alkyl or C₁₋₄fluoroalkyl); andR₆, R₇, R₈, R₉ are each independently selected from the group consistingof H, halo, CF₃, CN, NO₂, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₁₋₄ alkynyl, OH, OR(where OR is C₁₋₄ alkyl or C₁₋₄ fluoroalkyl), and SO₂R (where R is C₁₋₄alkyl or C₁₋₄ fluoroalkyl) compounds.

In accordance with another embodiment, the present invention providesmethods and uses of the inventive compounds for positive modulation ofGABA-A receptors in tissues and organs outside the brain.

In accordance with a further embodiment, the present invention providescompounds and methods for treating or preventing visceral pain andmodulating gut motility, such as in irritable bowel syndrome, in asubject comprising the administration of a therapeutically effectiveamount of a peripherally-restricted GABA-A receptor positive allostericmodulator.

In accordance with an embodiment, the present invention compounds forpositive modulation of GABA-A receptors in tissues and organs outsidethe brain selected from the group consisting of:

In accordance with another embodiment, the present invention providescompositions comprising compounds for positive modulation of GABA-Areceptors in tissues and organs outside the brain as disclosed herein,and at least one additional therapeutic agent.

In accordance with a further embodiment, the present invention providesmethods and uses of the compositions comprising compounds as disclosedherein, and at least one additional therapeutic agent for positivemodulation of GABA-A receptors in tissues and organs outside the brain.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other features, aspects, and advantages of the presentinvention are considered in more detail, in relation to the followingdescription of embodiments thereof shown in the accompanying drawings,in which:

FIG. 1 is a graph that shows dose response of Compound 1 (mg/kg) onwhole gut transit time (WGTT). Data are presented as mean±SEM(n=7-12). * Significant difference from vehicle (dose 0).

FIG. 2 is a graph showing time course of effect of Compound 1 (squares,3 mg/kg) on distal colon transit time (DCTT) compared to vehicle(diamonds). Data are presented as mean±SEM (n=7-8). * Significantdifference from vehicle group at same time point.

FIG. 3 is a graph that shows the effect of Compound 1 (mg/kg) on stoolweight (left) and water content (right). Data are presented as mean±SEM(n=7-8). * Significant difference from vehicle group (0 dose).

FIG. 4 shows various graphs of treatment with Compound 1 (10 mg/kg)attenuated pain sensitivity in IBS mice. The VMR to CRD was comparedbetween before (left) and after treatment (right) with vehicle(diamonds) or Compound 1 (squares). Data are presented as mean±SEM(n=3-4). The VMR to CRD in IBS mice treated with 10 mg/kg of Compound 1was significantly reduced when analyzed by Two-Way ANOVA.

DETAILED DESCRIPTION OF THE INVENTION

The invention summarized above may be better understood by referring tothe following description. This description of an embodiment, set outbelow to enable one to practice an implementation of the invention, isnot intended to limit the preferred embodiment, but to serve as aparticular example thereof. Those skilled in the art should appreciatethat they may readily use the conception and specific embodimentsdisclosed as a basis for modifying or designing other methods andsystems for carrying out the same purposes of the present invention.Those skilled in the art should also realize that such equivalentassemblies do not depart from the spirit and scope of the invention inits broadest form.

Overview

In accordance with an embodiment, the present invention provides methodsfor treatment of visceral pain and modulating gut motility in a subject,such as that caused by IBS, by positively modulating the GABA-A receptorin the enteric nervous system without the usual CNS side effects of GABAmodulation is provided. It is contemplated that the methods describedherein are effective in treating visceral pain caused by other ailments,not only IBS. Examples of non-IBS related ailments which can be treatedby the inventive methods, include functional abdominal pain, functionalidiopathic diarrhea, inflammatory bowel diseases, drug induced pain,bile salt malabsorption, lactase or other carbohydrate intolerance.Through modulation of physical properties such as membrane permeabilityand incorporation of functional groups known to enhance recognition byblood-brain barrier transporters, GABA-A receptor positive allostericmodulators used in the present invention, are restricted from the CNS sothey do not produce unwanted side effects such as sedation yet stillexert beneficial pharmacological effects on the enteric nervous system.

Pharmacological access to the CNS is restricted by the blood brainbarrier (BBB), a system that includes tight junctions between vascularendothelial cells and membrane transporters which work to minimize brainexposure of many circulating biomolecules, peptides, and drugs. Severaltherapeutically useful drugs take advantage of this restriction toprovide a peripheral benefit without CNS complications, such as thewell-known non-sedating antihistamines loratadine and cetirizine.²⁰Since all of the known GABA-A positive allosteric modulators, such asdiazepam and midazolam, were designed to treat CNS disorders;non-brain-penetrating analogs have not been previously described, oronly described as intermediates toward more useful compounds.

In accordance with some embodiments, the present invention provideschemical compounds according to formulas 1 and 2, and pharmaceuticallyacceptable salts, solvates, and stereoisomers thereof, or any prodrugequivalents (such as esters) thereof, where at least one of the R or Asubstituents contain a functional group that reduces blood-brain barrierpermeability, as shown below.

In accordance with an embodiment, the present invention provides acompound of formulas 1 and 2:

wherein, A₁, A₂, and A₃ are independently selected from C or N, where atleast one of A₁, A₂, or A₃ is a C unsubstituted or substituted with agroup consisting of alkyl, alkenyl, alkynyl, cycloalkyl,heterocycloalkyl, aryl, heteroaryl, —COOR₁₀, —COR₁₀, —OR₁₀, —NR₁₀R₁₁,and —CONR₁₀R₁₁;each of R₁₀ and R₁₁ is independently H, alkyl, alkenyl, alkynyl,cycloalkyl, heterocycloalkyl, aryl, or heteroaryl optionally substitutedwith one or more amidinyl, guanidinyl, phosphate, sulfate, tetrazole,3-hydroxyisoxazole, quaternary ammonium salts including urea, primaryamides, sulfonamides, sulfonyl ureas, acylamidines, acylguanidines, or—NR₁₂R₁₃ groups;each of R₁₂ and R₁₃ is independently H, —CONH₂, —SOONH₂, alkyl, alkenyl,alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;X is O;Y is selected from H, OH, OQ, and CO₂Q where Q is a prodrug thatliberates Y═H or Y═OH;Z is selected from oxygen and an electron lone pair;R₁ is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl,heteroaryl optionally substituted with one or more halo, CF₃, CN, NO₂,COOH, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₁₋₄ alkynyl, OH, OR (where OR is C₁₋₄alkyl or C₁₋₄ fluoroalkyl), SO₂R (where R is C₁₋₄ alkyl or C₁₋₄fluoroalkyl);R₅ is selected from the group consisting of aryl, heteroaryl, orcycloalkenyl groups optionally substituted with one or more halo, CF₃,CN, NO₂, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₁₋₄ alkynyl, OH, OR (where OR isC₁₋₄ alkyl or C₁₋₄ fluoroalkyl), and SO₂R (where R is C₁₋₄ alkyl or C₁₋₄fluoroalkyl); andR₆, R₇, R₈, R₉ are each independently selected from the group consistingof H, halo, CF₃, CN, NO₂, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₁₋₄ alkynyl, OH, OR(where OR is C₁₋₄ alkyl or C₁₋₄ fluoroalkyl), and SO₂R (where R is C₁₋₄alkyl or C₁₋₄ fluoroalkyl) compounds.

In accordance with an embodiment, the present invention providescompounds of formula 1 for positive modulation of GABA-A receptors intissues and organs outside the brain selected from the group consistingof:

In accordance with an embodiment, the present invention providescompounds of formula 2 for positive modulation of GABA-A receptors intissues and organs outside the brain selected from the group consistingof:

In accordance with another embodiment, the present invention providespharmaceutical compositions comprising the compounds of formulas 1 or 2,as described herein, and a pharmaceutically acceptable carrier.

Definitions

As used herein, the chemical terms used above are standard chemicalterminology. Sample definitions of such chemical substituents can befound in U.S. Pat. No. 8,530,438; which is incorporated herein byreference in its entirety.

As used herein, “peripherally restricted” or “restricted access to thecentral nervous system” generally refers to a compound that does notsubstantially cross an intact blood brain barrier of a subject. The termalso encompasses compounds that may cross an intact blood brain barrier,but upon administration is rapidly metabolized to a form that does notsubstantially cross an intact blood brain barrier of the subject. Acompound may be considered “peripherally restricted” if, uponadministration to a subject, less than 50%, less than 45%, less than40%, less than 35%, less than 30%, less than 25%, less than 20%, lessthan 15%, less than 10%, less than 9%, less than 8%, less than 7%, lessthan 6%, less than 5%, less than 4%, less than 3%, less than 2%, lessthan 1%, less than 0.5%, less than 0.1% of the compound crosses anintact blood brain barrier of the subject. In some embodiments, the term“peripherally restricted can mean that the concentration of a compoundin the brain compared to the concentration in the circulating plasma(brain:plasma) ratio of about 1:5, preferably 1:10 or greater. In oneexemplary embodiment the brain:plasma ratio is determined by measuringthe ratio of a compound in mice or rats.

As used herein, the term “an effective amount” or “a therapeuticallyeffective amount” refers to the amount of a compound that is sufficientto affect the intended application, including but not limited to diseasetreatment, as defined below. The therapeutically effective amount mayvary depending upon the intended treatment application (in vivo), or thesubject and disease condition being treated, e.g., the weight and age ofthe subject, the severity of the disease condition, the manner ofadministration and the like, which can readily be determined by one ofordinary skill in the art. The term also applies to a dose that willinduce a particular response in target cells. The specific dose willvary depending on the particular compounds chosen, the dosing regimen tobe followed, whether it is administered in combination with othercompounds, timing of administration, the tissue to which it isadministered, and the physical delivery system in which it is carried.

As used herein, the term “positive modulation” or “positive allostericmodulation” and all words stemming therefrom, refer to compounds thatbind to an allosteric site on a receptor complex and affect it in apositive manner. Affecting a receptor in a positive manner typicallymeans causing increased efficiency of the main receptor site. Increasedreceptor efficiency can mean potentially inducing a receptor to undergoa conformational change, or where the channel opens more frequently orfor longer periods of time when an agonist binds to the receptor.

As used herein, “visceral pain” refers to pain that results from theactivation of nociceptors of the thoracic, pelvic, or abdominal organs.Problems with organs, for example but not limited to, the stomach,kidney, gallbladder, urinary bladder, and intestines, can lead tovisceral pain. Such problems can include distension, perforation,inflammation, impaction, and constipation. The visceral pain can bediffuse, vague, dull, deep, squeezing, pressure-like, and difficult tolocalize. The visceral pain may be accompanied by symptoms such asnausea, vomiting, sweating, and changes in blood pressure, heart rate,and temperature. Visceral pain can often be experienced, or “referred”to different sites of the body.

As used herein, “gut motility” refers to stretching and contractions ofthe muscles of the gastrointestinal tract. Peristaltic movement is thecyclical relaxation of circular smooth muscles, followed by theirlongitudinal contraction. Gut motility can be impaired, which can leadto abnormal contractions, including spasms and paralysis.

As used herein, “irritable bowel syndrome” or “IBS” generally refers toa syndrome in which subjects experience recurrent or chronicgastrointestinal symptoms. Symptoms of IBS can include, e.g., abdominalpain, abdominal discomfort, constipation, diarrhea, mucus in the stool,abdominal bloating, or a combination of any of the above. IBS may bediagnosed when a person has had abdominal pain or discomfort at least 3times a month for the last 3 months without other disease or injury thatcould explain the pain. The pain or discomfort of IBS may occur with achange in stool frequency or consistency or be relieved by a bowelmovement. IBS can be classified into four subtypes based on a subject'susual stool consistency. The four subtypes of IBS are: IBS withconstipation (IBS-C), IBS with diarrhea (IBS-D), mixed IBS (IBS-M), andunsubtyped IBS (IBS-U). A subject with IBS-C may have hard or lumpystools at least 25 percent of the time, may have loose or watery stoolsless than 25 percent of the time, or a combination of the two. A subjectwith IBS-D may have loose or watery stools at least 25 percent of thetime, hard or lumpy stools less than 25 percent of the time, or acombination of the two. A subject with IBS-M may have hard or lumpystools at least 25 percent of the time and loose or watery stools atleast 25 percent of the time. A subject with IBS-U may have hard orlumpy stools less than 25 percent of the time, loose or watery stoolsless than 25 percent of the time, or a combination of the two.Constipation associated with IBS may be due to slow or delayed gastricmotility. In some embodiments, the subject with IBS has experiencedconstipation. IBS can be diagnosed in a subject by any methods known inthe art or otherwise described herein. For instance, IBS may bediagnosed by a health care provider. The health care provider mayconduct a physical exam and may take a medical history of the subject.IBS may be diagnosed if a subject has exhibited one or more symptoms ofIBS for at least 3, 4, 5, or 6 months, with one or more symptomsoccurring at least three times a month for the previous 3 months.Additional tests that may be useful in the diagnosis of IBS include, butare not limited to: a stool test, lower GI series, flexiblesigmoidoscopy, or colonoscopy.

The term “functional abdominal pain” or “functional abdominal painsyndrome” (FAPS) generally refers to a chronic and or frequentlyrecurring pain not associated with changes in bowel movement patterns orwith altered motility in the intestines. Normal abdominal activity maybe experienced as being painful and contribute to functional abdominalpain. Functional abdominal pain may be related to centralhypersensitivity, where the brain may fail to regulate pain signals fromthe gastrointestinal tract. While symptoms of FAPS can appear withoutapparent cause, they can also occur after infections or events thatstimulate the bowel and also after traumatic life events like the deathof a loved one, a divorce, or a history of sexual or physical abuse.During times of added stress, symptoms can worsen.

Repeated injury in the abdomen can cause nerve receptors to becomeoverly sensitive. For instance, if someone has had multiple abdominalsurgeries or an infection, a later painful occurrence may be experiencedas more painful than previously. Even normal abdominal activity may beexperienced as being painful. It is as if the volume has been turned upon a stereo receiver. This condition is called visceral hypersensitivity(i.e., increased sensitivity of the intestines). Furthermore althoughthe brain has an ability to “turn down” the pain signals from the GItract with FAPS, this ability is reduced, so even small amounts ofintestinal disturbance can be amplified to produce severe pain (centralhypersensitivity). So these individuals have an altered “braingut axis”where there is a failure of the brain to regulate even normal gut nerveactivity leading to increased pain.

For purposes of the present invention, the term “diarrhea,” as usedherein means frequent, poorly formed, loose, watery stools of a subject.A subject having diarrhea means the subject is passing loose stools atleast three times a day. The term “acute diarrhea” is a common problemthat usually lasts <7 days but can last in a protracted or prolongedform for <21 days. Diarrhea lasting more than 2 days is often a sign ofan enteropathogenic infection. The term “chronic diarrhea” meansdiarrhea that lasts at least 4 weeks. Chronic diarrhea symptoms may becontinual or intermittent. The term “traveler's diarrhea” meansdiarrheal symptoms associated with travel-related infection. It may becaused by many different organisms, including bacteria such as E. coli,Salmonella, Shigella, Campylobacter, Aeromonas, Plesiomonas, andvibrios; parasites such as Giardia, Entamoeba histolytica,Cryptosporidium, and Cyclospora; and viruses. In addition to diarrhea,symptoms may include nausea, vomiting, abdominal pain, fever, sweats,chills, headache, and malaise. Diarrhea may also be the result of foodborne enteropathogens. Typical food borne pathogens are E. coli,Salmonella, Shigella, Yersinia, and Campylobacter.

Diarrhea of any duration may cause dehydration, which means the bodylacks enough fluid and electrolytes—chemicals in salts, includingsodium, potassium, and chloride—to function properly. Loose stoolscontain more water and electrolytes and often weigh more than solidstools.

The term “functional idiopathic diarrhea” generally refers to diarrheaoccurring for unknown reasons. Idiopathic diarrhea generally lasts forless than 5 days and often resolves within 2 or 3 days. Diarrheagenerally means an increased frequency or decreased consistency of bowlmovements. Diarrhea can also mean an increase in stool weight.

The term “inflammatory bowel diseases” generally refers to chronicinflammation of all or part of the gastrointestinal tract. Symptoms ofinflammatory bowel diseases can involve severe diarrhea, pain, abdominalpain and cramping, blood in the subject's stool, fatigue, reducedappetite and weight loss, or a combination of any of the above.Additional symptoms of inflammatory diseases also include bowelobstruction, ulcers, perforated colon, fistulas, anal fissure,malnutrition, severe dehydration, increased risk of colon cancer. Nonlimiting examples of inflammatory bowel diseases include Crohn's diseaseand ulcerative colitis, which itself may have several differentsubtypes, such as ulcerative proctitis, proctosigmoiditis, left-sidedcolitis, pancolitis, acute severe ulcerative colitis. Inflammatory boweldisease can be diagnosed in a subject by any methods known in the art orotherwise described herein. For instance, inflammatory bowel disease maybe diagnosed by a health care provider. A physician or health careprovider may perform or order a combination of tests to confirm thepresence of inflammatory bowel disease, including, but not limited to,blood tests of anemia or infection, fecal occult blood test,colonoscopy, flexible sigmoidoscopy, upper endoscopy, capsule endoscopy,double-balloon endoscopy, x-ray, computerized tomography scan, magneticresonance imaging, or small bowel imaging.

The term “drug induced pain” is the unintended effect of a drug, whichresults in symptoms sufficient to prompt a patient to seek medicalattention and/or require hospitalization. Examples of medications thatare known to induce pain include: chemotherapy drugs, which are known tocause nerve damage in the form of peripheral neuropathy. In fact, theonset of peripheral neuropathy can be the primary limiting factor forthe amount and duration of the chemotherapy; cholesterol-lowering drugsthat people take medications to lower cholesterol levels are known tocause muscle pain and weakness is well known to be a resultingside-effect from cholesterol-lowering drugs; and opioids (hydrocodone,hydromorphone, oxycodone, morphine) when used for years and the painbecomes worse, this vicious pain cycle can be a result of opioid-inducedhyperalgesia.

Proteins, carbohydrates, fats, and most fluids are absorbed in the smallintestine (small bowel). Malabsorption syndrome occurs when somethingprevents the bowel from absorbing important nutrients and fluids. Theproblem may be caused by inflammation, disease, or injury. Sometimes,the condition may be the result of the body's failure to produce enzymesneeded to digest some foods. Factors that may cause malabsorptionsyndrome include: antibiotic use; conditions such as celiac disease,chronic pancreatitis, cystic fibrosis, and dairy protein allergies;congenital (birth) defects or diseases of the gall bladder, liver, orpancreas; damage to the intestine (from infection, inflammation, injury,or surgery); and radiation therapy (which may injure the mucosal liningof the bowel). Symptoms can include bloating, flatulence, or explosivediarrhea.

The term “bile salt malabsorption” generally refers increased bile saltsin the gastrointestinal tract, which can cause fluid to be pumped intothe colon, causing diarrhea. Other symptoms of bile salt malabsorptioncan also include cramping in the abdomen, smelly wind, weight loss, gallstones, and kidney stones. There are currently three recognized types ofbile salt malabsorption: (1) bile salt malabsorption, secondary to ilealresection, or ileal inflammation, (2) idiopathic/primary bile saltmalabsorption, and (3) secondary to various gastrointestinal diseases.Bile salt malabsorption can be diagnosed in a subject by any methodsknown in the art or otherwise described herein. For instance, bile saltmalabsorption may be diagnosed by a health care provider. A physician orhealth care provider may perform or order a combination of tests toconfirm the presence of bile salt malabsorption, including, but notlimited to, a SeHCAT scan, measurement of 7alpha-hydroxy-4-cholesten-3-one, and fasting blood FGF19 values.

The terms “treat” and “prevent” as well as words stemming therefrom, asused herein, refer to an approach for obtaining beneficial or desiredresults including but not limited to a therapeutic benefit and/or aprophylactic benefit. A therapeutic benefit can mean eradication oramelioration of the underlying disorder being treated. Also, atherapeutic benefit can be achieved with the eradication or ameliorationof one or more of the physiological symptoms associated with theunderlying disorder such that an improvement is observed in the subject,notwithstanding that the subject may still be afflicted with theunderlying disorder. A prophylactic effect includes delaying oreliminating the appearance of a disease or condition, delaying oreliminating the onset of symptoms of a disease or condition, slowing,halting, or reversing the progression of a disease or condition, or anycombination thereof. For prophylactic benefit, the compositions may beadministered to a subject at risk of developing a particular disease, orto a subject reporting one or more of the physiological symptoms of adisease, even though a diagnosis of this disease may not have been made.Therefore, there are varying degrees of treatment or prevention of whichone of ordinary skill in the art recognizes as having a potentialbenefit or therapeutic effect. In this respect, the inventive methodscan provide any amount of any level of treatment or prevention of aGABA-A mediated disease in a mammal. Furthermore, the treatment orprevention provided by the inventive method can include treatment orprevention of one or more conditions or symptoms of a disease, e.g.,IBS, being treated or prevented.

As used herein, the term “subject” refers to any mammal, including, butnot limited to, mammals of the order Rodentia, such as mice andhamsters, and mammals of the order Logomorpha, such as rabbits. It ispreferred that the mammals are from the order Carnivora, includingFelines (cats) and Canines (dogs). It is more preferred that the mammalsare from the order Artiodactyla, including Bovines (cows) and Swines(pigs) or of the order Perssodactyla, including Equines (horses). It ismost preferred that the mammals are of the order Primates, Ceboids, orSimoids (monkeys) or of the order Anthropoids (humans and apes). Anespecially preferred mammal is the human. In some cases, the subject innot an adult.

The term “alkyl,” as used herein, refers to a hydrocarbon chain that isa straight chain or branched chain, containing the indicated number ofcarbon atoms. For example, C₁-C₄ alkyl group indicates that the grouphas from 1 to 4 (inclusive) carbon atoms in it. Similarly, C₁-C₁₀ alkylgroup indicates that the group has from 1 to 10 (inclusive) carbon atomsin it. Unless stated otherwise specifically in the specification, analkyl group is optionally substituted.

The term “alkenyl,” as used herein, refers to a hydrocarbon chain thatis a straight chain or branched chain, containing the indicated numberof carbon atoms having one or more carbon-carbon double bonds. Forexample, C₂-C₄ alkenyl group indicates that the group has from 2 to 4(inclusive) carbon atoms in it. Similarly, C₂-C₁₀ alkenyl groupindicates that the group has from 2 to 10 (inclusive) carbon atoms init. Unless stated otherwise specifically in the specification, analkenyl group is optionally substituted.

The term “alkynyl,” as used herein, refers to a hydrocarbon chain thatis a straight chain or branched chain, containing the indicated numberof carbon atoms having one or more carbon-carbon triple bonds. Forexample, C₂-C₄ alkynyl group indicates that the group has from 2 to 4(inclusive) carbon atoms in it. Similarly, C₂-C₁₀ alkynyl groupindicates that the group has from 2 to 10 (inclusive) carbon atoms init. Unless stated otherwise specifically in the specification, analkynyl group is optionally substituted.

The term “halo” or “halogen,” as used herein, refers to fluoro, chloro,bromo, or iodo.

The term “cycloalkyl” or “carbocyclic ring”, as used herein, refers to astable non-aromatic monocyclic or polycyclic hydrocarbon radicalconsisting solely of carbon and hydrogen atoms, which may include fusedor bridged ring systems, having from three to fifteen carbon atoms, andwhich is saturated or unsaturated and attached to the rest of themolecule by a single bond. Monocyclic radicals include, for example,cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, andcyclooctyl. Polycyclic radicals include, for example, adamantyl,norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.A “cycloalkenyl” is a cycloalkyl comprising one or more carbon-carbondouble bonds within the ring. Unless otherwise stated specifically inthe specification, a cycloalkyl (or cycloalkenyl) group is optionallysubstituted.

The term “heterocycloalkyl” or “heterocyclic ring” refers to asubstituted or unsubstituted 3-, 4-, 5-, 6- or 7-membered saturated orpartially unsaturated ring containing one, two, or three heteroatoms,independently selected from oxygen, nitrogen and sulfur;

heterocycloalkyl may be unsubstituted or substituted with one or moresubstituents. The heterocycloalkyl may be optionally fused to anothercycloalkyl, heterocycloalkyl, or an aryl. For example, to a benzo group.

The term “aryl”, as used herein, refers to a hydrocarbon ring systemradical comprising,e.g., 6 to 18 carbon atoms and at least one aromaticring. The aryl radical can be a monocyclic, bicyclic, tricyclic, ortetracyclic ring system, which may include fused or bridged ringsystems. Aryl radicals can include, but not limited to, aryl radicalsderived from aceanthrylene, acenaphthylene, acephenanthrylene,anthracene, azulene, benzene, chrysene, fluoranthene, fluorene,as-indacene, s-indacene, indane, indene, naphthalene, phenalene,phenanthrene, pleiadene, pyrene, and triphenylene. Unless statedotherwise specifically in the specification, the term “aryl” or theprefix “ar-” (such as in “aralkyl”) is meant to include aryl radicalsthat are optionally substituted.

The term “Heteroaryl”, as used herein, refers to a 5- to 14-memberedring system radical comprising one or more heteroatoms selected from thegroup consisting of nitrogen, oxygen, and sulfur. The heteroaryl radicalmay be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system,which may include fused or bridged ring systems; the nitrogen, carbon orsulfur atoms in the heteroaryl radical may be optionally oxidized; andthe nitrogen atom may be optionally quaternized. Exemplary heteroarylgroups may include, but not limited to, azepinyl, acridinyl,benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl,benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl,benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl,benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl,benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl(benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl,carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl,furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl,isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl,isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl,oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl,1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl,phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl,pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl,quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl,tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl,triazinyl, and thiophenyl (i.e., thienyl). Unless stated otherwisespecifically in the specification, a heteroaryl group is optionallysubstituted.

Exemplary Pharmaceutical Compositions

Accordingly, included within the compounds of the present invention arethe tautomeric forms of the disclosed compounds, isomeric formsincluding enantiomers, stereoisomers, and diastereoisomers, and thepharmaceutically-acceptable salts thereof.

The salts of the compounds of formulas 1 or 2 used in the method oftreatment described herein will be pharmaceutically acceptable salts. Aperson of ordinary skill in the art would recognize thatnon-pharmaceutically acceptable salts may be used as intermediaries inthe preparation of the compounds of formula I or its derivatives andtheir pharmaceutically acceptable salts. When the compound of thepresent invention is acidic, suitable “pharmaceutically acceptablesalts” refers to salts prepared from pharmaceutically acceptablenon-toxic bases including inorganic bases and organic bases. Saltsderived from inorganic bases include aluminum, ammonium, calcium,copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous,potassium, sodium, zinc and the like. Particularly preferred are theammonium, calcium, magnesium, potassium and sodium salts. Salts derivedfrom pharmaceutically acceptable organic non-toxic bases include saltsof primary, secondary and tertiary amines, substituted amines includingnaturally occurring substituted amines, cyclic amines and basic ionexchange resins, such as arginine, betaine caffeine, choline,N,N′1-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol,2-dimethylaminoethanol, ethanolamine, ethylenediamine,N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine,hydrabamine, isopropylamine, lysine, methylglucamine, morpholine,piperazine, piperidine, polyamine resins, procaine, purines,theobromine, triethylamine, trimethylamine tripropylamine, tromethamineand the like.

When the compound of the present invention is basic, salts may beprepared from pharmaceutically acceptable non-toxic acids, includinginorganic and organic acids. Such acids include acetic, benzenesulfonic,benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic,glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic,mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic,phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and thelike. Particularly preferred are citric, hydrobromic, hydrochloric,maleic, phosphoric, sulfuric and tartaric acids. In a further embodimentof the present invention, a formulation comprising a compound offormulas 1 and 2, or a salt, solvate, or stereoisomer thereof, and asuitable pharmaceutically acceptable carrier is provided as understoodby a person of ordinary skill in the art.

In yet a further aspect of the present invention, a method for treatinga patient with IBS is provided. The method comprises the steps ofadministering one or more compounds of formulas 1 and 2, or a salt,solvate, or stereoisomer thereof, or a derivative thereof to a subject.The compounds can be provided with a pharmaceutically acceptablecarrier, when necessary.

Carriers and Excipients

With respect to pharmaceutical compositions described herein, thepharmaceutically acceptable carrier can be any of those conventionallyused, and is limited only by physico-chemical considerations, such assolubility and lack of reactivity with the active compound(s), and bythe route of administration. The pharmaceutically acceptable carriersdescribed herein, for example, vehicles, adjuvants, excipients, anddiluents, are well-known to those skilled in the art and are readilyavailable to the public. Examples of the pharmaceutically acceptablecarriers include soluble carriers such as known buffers which can bephysiologically acceptable (e.g., phosphate buffer) as well as solidcompositions such as solid-state carriers or latex beads. It ispreferred that the pharmaceutically acceptable carrier be one which ischemically inert to the active agent(s), and one which has little or nodetrimental side effects or toxicity under the conditions of use.

The carriers or diluents used herein may be solid carriers or diluentsfor solid formulations, liquid carriers or diluents for liquidformulations, or mixtures thereof.

Solid carriers or diluents include, but are not limited to, gums,starches (e.g., corn starch, pregelatinized starch), sugars (e.g.,lactose, mannitol, sucrose, dextrose), cellulosic materials (e.g.,microcrystalline cellulose), acrylates (e.g., polymethylacrylate),calcium carbonate, magnesium oxide, talc, or mixtures thereof.

For liquid formulations, pharmaceutically acceptable carriers may be,for example, aqueous or non-aqueous solutions, suspensions, emulsions oroils. Examples of non-aqueous solvents are propylene glycol,polyethylene glycol, and injectable organic esters such as ethyl oleate.Aqueous carriers include, for example, water, alcoholic/aqueoussolutions, cyclodextrins, emulsions or suspensions, including saline andbuffered media.

Examples of oils are those of petroleum, animal, vegetable, or syntheticorigin, for example, peanut oil, soybean oil, mineral oil, olive oil,sunflower oil, fish-liver oil, sesame oil, cottonseed oil, corn oil,olive, petrolatum, and mineral. Suitable fatty acids for use inparenteral formulations include, for example, oleic acid, stearic acid,and isostearic acid. Ethyl oleate and isopropyl myristate are examplesof suitable fatty acid esters.

In addition, in an embodiment, the compounds of the present inventionmay further comprise, for example, binders (e.g., acacia, cornstarch,gelatin, carbomer, ethyl cellulose, guar gum, hydroxypropyl cellulose,hydroxypropyl methyl cellulose, povidone), disintegrating agents (e.g.,cornstarch, potato starch, alginic acid, silicon dioxide, croscarmelosesodium, crospovidone, guar gum, sodium starch glycolate), buffers (e.g.,Tris-HCl, acetate, phosphate) of various pH and ionic strength,additives such as albumin or gelatin to prevent absorption to surfaces,detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts),protease inhibitors, surfactants (e.g. sodium lauryl sulfate),permeation enhancers, solubilizing agents (e.g., cremophor, glycerol,polyethylene glycerol, benzlkonium chloride, benzyl benzoate,cyclodextrins, sorbitan esters, stearic acids), anti-oxidants (e.g.,ascorbic acid, sodium metabisulfite, butylated hydroxyanisole),stabilizers (e.g., hydroxypropyl cellulose, hyroxypropylmethylcellulose), viscosity increasing agents (e.g., carbomer, colloidalsilicon dioxide, ethyl cellulose, guar gum), sweetners (e.g., aspartame,citric acid), preservatives (e.g., thimerosal, benzyl alcohol,parabens), lubricants (e.g., stearic acid, magnesium stearate,polyethylene glycol, sodium lauryl sulfate), flow-aids (e.g., colloidalsilicon dioxide), plasticizers (e.g., diethyl phthalate, triethylcitrate), emulsifiers (e.g., carbomer, hydroxypropyl cellulose, sodiumlauryl sulfate), polymer coatings (e.g., poloxamers or poloxamines),coating and film forming agents (e.g., ethyl cellulose, acrylates,polymethacrylates), and/or adjuvants.

In some embodiments, the pharmaceutically acceptable carrier comprisesmore than 90%, more than 80%, more than 70%, more than 60%, more than50%, more than 40%, more than 30%, more than 20%, more than 10%, morethan 9%, more than 8%, more than 6%, more than 5%, more than 4%, morethan 3%, more than 2%, more than 1%, more than 0.5%, more than 0.4%,more than 0.3%, more than 0.2%, more than 0.1%, more than 0.09%, morethan 0.08%, more than 0.07%, more than 0.06%, more than 0.05%, more than0.04%, more than 0.03%, more than 0.02%, more than 0.01%, more than0.009%, more than 0.008%, more than 0.007%, more than 0.006%, more than0.005%, more than 0.004%, more than 0.003%, more than 0.002%, more than0.001%, more than 0.0009%, more than 0.0008%, more than 0.0007%, morethan 0.0006%, more than 0.0005%, more than 0.0004%, more than 0.0003%,more than 0.0002%, or more than 0.0001% of the pharmaceuticalcomposition by w/w, w/v or v/v.

In some embodiments, the concentration of the compound in thecomposition comprises less than 100%, less than 90%, less than 80%, lessthan 70%, less than 60%, less than 50%, less than 40%, less than 30%,less than 20%, less than 10%, less than 9%, less than 8%, less than 6%,less than 5%, less than 4%, less than 3%, less than 2%, less than 1%,less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, lessthan 0.1%, less than 0.09%, less than 0.08%, less than 0.07%, less than0.06%, less than 0.05%, less than 0.04%, less than 0.03%, less than0.02%, less than 0.01%, less than 0.009%, less than 0.008%, less than0.007%, less than 0.006%, less than 0.005%, less than 0.004%, less than0.003%, less than 0.002%, less than 0.001%, less than 0.0009%, less than0.0008%, less than 0.0007%, less than 0.0006%, less than 0.0005%, lessthan 0.0004%, less than 0.0003%, less than 0.0002%, or less than 0.0001%of the pharmaceutical composition by w/w, w/v or v/v.

In some embodiments, the concentration of the compound is in the rangeof about 0.0001% to about 50%, about 0.001% to about 40%, about 0.01% toabout 20%, about 0.02% to about 29%, about 0.03% to about 28%, about0.04% to about 27%, about 0.05% to about 26%, about 0.06% to about 25%,about 0.07% to about 24%, about 0.08% to about 23%, about 0.09% to about22%, about 0.1% to about 21%, about 0.2% to about 20%, about 0.3% toabout 19%, about 0.4% to about 18%, about 0.5% to about 17%, about 0.6%to about 16%, about 0.7% to about 15%, about 0.8% to about 14%, about0.9% to about 12%, about 1% to about 10% of the pharmaceuticalcomposition by w/w, w/v or v/v.

In some embodiments, the concentration of the compound is in the rangeof about 0.0001% to about 5%, about 0.001% to about 4%, about 0.01% toabout 2%, about 0.02% to about 1%, or about 0.05% to about 0.5% of thepharmaceutical composition by w/w, w/v or v/v.

In some embodiments, the amount of the compound in the pharmaceuticalcomposition is about 0.00001 mg, 0.0001 mg, 0.001 mg, 0.005 mg, 0.01 mg,0.05 mg, 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 4 mg, 8 mg, 10 mg, 12 mg,14 mg, 16 mg, 18 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 150mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1 g, 1.1 g,1.2 g, 1.3 g, 1.4 g, 1.5 g, 1.6 g, 1.7 g, 1.8 g, 1.9 g, 2 g, 2.5 g, 3 g,3.5 g, 4 g, 4.5 g, 5 g, 6 g, 7 g, 8 g, 9 g, or 10 g.

Exemplary Modes of Administration

Administration of a pharmaceutical composition as described herein canbe performed by any method that enables delivery of the compound to thesite of action. The composition may be administered orally,parenterally, enterally, intraperitoneally, topically, transdermally,ophthalmically, intranasally, locally, non-orally, via spray,subcutaneously, intravenously, intratonsillary, intramuscularly,buccally, sublingually, rectally, intra-arterially, by infusion, orintrathecally. In some embodiments, the composition is administeredorally. In some cases, the oral administration may compriseadministration of any of the oral dosage forms as described herein. Insome cases, a composition described herein is administered sublingually.In some cases, a composition described herein is administeredtransdermally, e.g., via transdermal patch. The effective amount of acompound administered will be dependent on the subject being treated,the severity of the disorder or condition, the rate of administration,the disposition of the compound and the discretion of the prescribingphysician.

Pharmaceutical Compositions for Oral Administration

The pharmaceutical composition comprising an effective amount of acompound can be formulated for oral administration. In some embodiments,the pharmaceutical composition comprising an effective amount of acompound for oral administration is a solid pharmaceutical composition.In some embodiments, the solid pharmaceutical composition may bepresented as discrete (e.g., unit) oral dosage forms. Non-limitingexamples of discrete oral dosage forms include tablets, capsules,caplets, gelatin capsules, sustained release formulations, lozenges,thin films, lollipops, chewing gum. In some embodiments, the discreteoral dosage form is an orally disintegrating oral dosage form, such as,an orally disintegrating tablet.

In some embodiments, the pharmaceutical composition comprising aneffective amount of a compound for oral administration is a liquidpharmaceutical composition. Non-limiting examples of liquid compositionsfor oral administration include hydrophilic suspensions, emulsions,liquids, gels, syrups, slurries, solutions, elixirs, softgels,tinctures, and hydrogels. In some embodiments, solid or liquidcompositions comprising an effective amount of a compound for oraladministration comprise various sweetening or flavoring agents, orcoloring agents. Examples of coloring agents include dyes suitable forfood such as those known as F.D. & C. dyes and natural coloring agentssuch as grape skin extract, beet red powder, beta carotene, annato,carmine, turmeric, paprika, and so forth. Derivatives, analogues, andisomers of any of the above colored compound also may be used. Thechoice of carrier will be determined, in part, by the particularcompound, as well as by the particular method used to administer thecompound. Accordingly, there are a variety of suitable formulations ofthe pharmaceutical composition of the invention. The followingformulations for parenteral, subcutaneous, intravenous, intramuscular,intraarterial, intrathecal and interperitoneal administration areexemplary, and are in no way limiting. More than one route can be usedto administer the compounds, and in certain instances, a particularroute can provide a more immediate and more effective response thananother route.

Pharmaceutical Compositions for Injection or Parenteral Administration

Parenteral vehicles (for subcutaneous, intravenous, intraarterial, orintramuscular injection) include, for example, sodium chloride solution,Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's andfixed oils. Formulations suitable for parenteral administration include,for example, aqueous and non-aqueous, isotonic sterile injectionsolutions, which can contain anti-oxidants, buffers, bacteriostats, andsolutes that render the formulation isotonic with the blood of theintended recipient, and aqueous and non-aqueous sterile suspensions thatcan include suspending agents, solubilizers, thickening agents,stabilizers, and preservatives.

Intravenous vehicles include, for example, fluid and nutrientreplenishers, electrolyte replenishers such as those based on Ringer'sdextrose, and the like. Examples are sterile liquids such as water andoils, with or without the addition of a surfactant and otherpharmaceutically acceptable adjuvants. In general, water, saline,aqueous dextrose and related sugar solutions, and glycols such aspropylene glycols or polyethylene glycol are preferred liquid carriers,particularly for injectable solutions. Suitable soaps for use inparenteral formulations include, for example, fatty alkali metal,ammonium, and triethanolamine salts, and suitable detergents include,for example, (a) cationic detergents such as, for example, dimethyldialkyl ammonium halides, and alkyl pyridinium halides, (b) anionicdetergents such as, for example, alkyl, aryl, and olefin sulfonates,alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates,(c) nonionic detergents such as, for example, fatty amine oxides, fattyacid alkanolamides, and polyoxyethylenepolypropylene copolymers, (d)amphoteric detergents such as, for example, alkyl-β-aminopropionates,and 2-alkyl-imidazoline quaternary ammonium salts, and (e) mixturesthereof.

The parenteral formulations will typically contain from about 0.5% toabout 25% by weight of the compounds in solution. Preservatives andbuffers may be used. In order to minimize or eliminate irritation at thesite of injection, such compositions may contain one or more nonionicsurfactants, for example, having a hydrophile-lipophile balance (HLB) offrom about 12 to about 17. The quantity of surfactant in suchformulations will typically range from about 5% to about 15% by weight.Suitable surfactants include, for example, polyethylene glycol sorbitanfatty acid esters, such as sorbitan monooleate and the high molecularweight adducts of ethylene oxide with a hydrophobic base, formed by thecondensation of propylene oxide with propylene glycol.

The parenteral formulations can be presented in unit-dose or multi-dosesealed containers, such as ampoules and vials, and can be stored in afreeze-dried (lyophilized) condition requiring only the addition of thesterile liquid excipient, for example, water, for injections,immediately prior to use. Extemporaneous injection solutions andsuspensions can be prepared from sterile powders, granules, and tablets.

Injectable formulations are in accordance with the invention. Therequirements for effective pharmaceutical carriers for injectablecompositions are well-known to those of ordinary skill in the art (see,e.g., Pharmaceutics and Pharmacy Practice, J.B. Lippincott Company,Philadelphia, P.a., Banker and Chalmers, eds., pages 238-250 (1982), andASHP Handbook on Injectable Drugs, Trissel, 15th ed., pages 622-630(2009)).

Other Pharmaceutical Compositions

Alternatively, the compounds of the present invention can be modifiedinto a depot form, such that the manner in which the compound isreleased into the body to which it is administered is controlled withrespect to time and location within the body (see, for example, U.S.Pat. No. 4,450,150). Depot forms of compounds can be, for example, animplantable composition comprising the compound and a porous ornon-porous material, such as a polymer, wherein the compound isencapsulated by or diffused throughout the material and/or degradationof the non-porous material. The depot is then implanted into the desiredlocation within the body and the compounds are released from the implantat a predetermined rate.

In one embodiment, the compounds of the present invention providedherein can be controlled release compositions, i.e., compositions inwhich the one or more compounds are released over a period of time afteradministration. Controlled or sustained release compositions includeformulation in lipophilic depots (e.g., fatty acids, waxes, oils). Inanother embodiment the composition is an immediate release composition,i.e., a composition in which all or substantially all of the compound isreleased immediately after administration.

In yet another embodiment, the compounds of the present invention can bedelivered in a controlled release system. For example, the agent may beadministered using intravenous infusion, an implantable osmotic pump, atransdermal patch, or other modes of administration. In an embodiment, apump may be used. In one embodiment, polymeric materials can be used. Inyet another embodiment, a controlled release system can be placed inproximity to the therapeutic target, i.e., the brain, thus requiringonly a fraction of the systemic dose (see, e.g., Design of ControlledRelease Drug Delivery Systems, Xiaoling Li and Bhaskara R. Jasti eds.(McGraw-Hill, 2006)).

In an embodiment, the pharmaceutical compositions of the presentinvention comprise the compounds of the present invention, for example,the compounds disclosed herein, and/or their salts, solvates orstereoisomers thereof, and optionally, one or more additionaltherapeutic agents, such as, for example, 5-HT receptor inhibitors,antibiotics, anti-inflammatory, immunomodulators, together with apharmaceutically acceptable carrier.

Examples of antibiotic agents suitable for use in pharmaceuticalcomposition comprising the compounds heretofore described above and oneor more antibiotic agents include, for example, quinolone antibiotics,such as levofloxacin, ciprofloxacin, ibafloxacin, pradofloxacin,rosoxacin, and sarafloxacin. Other suitable antibiotics aretrimethoprim-sulfamethoxazole mixtures such as Bactrim®. Alternativesinclude rifaximin and azithromycin. Dosages vary with the weight and ageof the subject to be treated. Typically, quinolone antibiotics andtrimethoprim-sulfamethoxazole mixtures are given at dosages between 250and 500 mg daily. For trimethoprim-sulfamethoxazole, the dosages aregenerally between about 5 mg/kg and 25 mg/kg. For rifaximin the dosageranges from 100 mg to about 500 mg, with 200 mg being preferred.Azithromycin is typically administered at 250-500 mg/day. The dosagesrequired are well within the knowledge of those of ordinary skill in theart.

General Considerations

For purposes of the invention, the amount or dose of the compounds,salts, solvates, or stereoisomers of any one the compounds of Formula I,as set forth above, administered should be sufficient to effect, e.g., atherapeutic or prophylactic response, in the subject over a reasonabletime frame. The dose will be determined by the efficacy of theparticular compound and the condition of a human, as well as the bodyweight of a human to be treated.

The dose of the compounds, salts, solvates, or stereoisomers of any onethe compounds as set forth above, of the present invention also will bedetermined by the existence, nature and extent of any adverse sideeffects that might accompany the administration of a particularcompound.

Typically, an attending physician will decide the dosage of the compoundwith which to treat each individual patient, taking into consideration avariety of factors, such as age, body weight, general health, diet, sex,compound to be administered, route of administration, and the severityof the condition being treated. By way of example, and not intending tolimit the invention, the dose of the compound can be about 0.001 toabout 1000 mg/kg body weight of the subject being treated/day, fromabout 0.01 to about 100 mg/kg body weight/day, about 0.1 mg to about 10mg/kg body weight/day. The several aspects of the present invention,described above, are shown in the following examples.

EXAMPLES Example 1.8-Chloro-6-(2-fluorophenyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxylicacid

Step 1: Diethyl 2-[(2-chloroacetyl)amino]propanedioate

To a stirring mixture of diethyl 2-aminopropanedioate hydrochloride (10g, 47.25 mmol) and chloroacetyl chloride (5.33 g, 47.25 mmol) in1,2-dichloroethane (120 ml) at 0° C., Triethylamine (19.65 ml, 141.75mmol) was added slowly into the solution. The solution was heated to itsboiling point for 10 min., then it was cooled to room temperature andstirred at room temperature overnight. The solution was diluted withdichloromethane (100 ml). The solution was filtered to remove thetriethyl amine hydrochloride salt. The filtrate was extracted with HClsolution (1 N, 2×30 ml), water (1×50 ml) and brine (1×50 mL), dried oversodium sulfate. The solution was filtered and concentrated. The residuewas recrystallized in cyclohexane to give the title compound as slightlycolored solid (7.2 g, 61%) (Kitagawa, Nakamura, Masai, “Synthesis andRoot Growth-Inhibitory Activity of 2- and3-(Haloacetylamino)-1-(2furyl)propanoic Acids” Chem. Pharm. Bull., 51(8)994-998 (2003). MS (ES+) m/z 252.0 [M+H]⁺. 1H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.28-1.39 (m, 6H) 4.10-4.17 (m, 2H) 4.24-4.39 (m,4H) 5.16 (d, J=6.82 Hz, 1H)

Step 2: Diethyl2-[(2-chloroacetyl)amino]-2-[(E)-[4-chloro-2-(2-fluorobenzoyl)phenyl]azo]propanedioate

To a stirring solution of(2-amino-5-chloro-phenyl)-(2-fluorophenyl)methanone (6.94 g, 27.8 mmol)in acetic acid (26 ml) with stirring at room temperature, concentratedhydrochloric acid (6.95 ml, 83.4 mmol) was added. Sodium nitrite (5 M)solution (5.56 ml, 27.81 mmol) was added. The solution was stirred atroom temperature for 15 min. Ice (19 g) was added. The solution ofdiethyl 2-[(2-chloroacetyl)amino]propanedioate (7.0 g, 27.8 mmol)dissolved in acetone (60 ml) was added dropwise quickly. The solutionwas cooled to 0° C. Saturated potassium carbonate solution (4.2 ml) wasadded. The pH of the solution was between 5 and 6.5. The solution wasstirred at room temperature for 1 hr. The solution was extracted withethyl acetate (2×70 ml). The combined organic solution was washed withwater (35 ml) and brine (35 ml), dried over sodium sulfate. The solutionwas filtered and concentrated. The residue was purified over ISCO elutedwith ethyl acetate/hexane (0-30%) to give the title compound as deepcolored oil (10.8 g, 76%). MS (ES+) m/z 534.0 [M+Na]⁺.

1H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.24-1.36 (m, 6H), 3.87 (s, 2H),4.21-4.36 (m, 4H), 7.49-7.80 (m, 7H)

Step 3:1-[4-chloro-2-(2-fluorobenzoyl)phenyl]-5-(chloromethyl)-1,2,4-triazole-3-carboxylicacid

To a stirring solution of diethyl2-[(2-chloroacetyl)amino]-2-[(E)-[4-chloro-2-(2-fluorobenzoyl)phenyl]azo]propanedioate(1.33 g, 2.5 mmol) in methanol (20 ml), sodium hydroxde solution (1 N,7.8 ml, 7.8 mmol) was added. The solution was stirred at roomtemperature for 4 hrs. The product was precipitated by adding 10% HClsolution to adjust the solution to acidic. The solution was extractedwith dichloromethane (3×50 ml). The combined DCM solution was washedwith brine, dried over sodium sulfate. The solution was filtered andconcentrated. The residue was recrystallized in dichloromethane/hexaneto give the title compound as white solid (0.86 g, 84%). MS (ES+) m/z394.0 [M+H]⁻

1H NMR (400 MHz, DMSO-d6) δ ppm 4.87 (s, 2H), 7.15-7.26 (m, 2H) 7.49(td, J=7.52, 1.89 Hz, 1H) 7.55-7.66 (m, 1H) 7.83-7.94 (m, 2H) 8.00 (dd,J=8.46, 2.40 Hz, 1H)

Step 4:8-Chloro-6-(2-fluorophenyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxylicacid

To a stirring solution of ammonia in methanol (7 N, 5 ml) at 0° C.,1-[4-chloro-2-(2-fluorobenzoyl)phenyl]-5-(chloromethyl)-1,2,4-triazole-3-carboxylicacid (180 mg, 0.46 mmol) in methanol (2 ml) was added. Potassium iodide(4 mg) was also added. The solution was stirred at room temperature forthree days. The solution was concentrated. The residue was purified overISCO eluted with methanol (10% acetic acid)/DCM (0-40%). The residuefrom ISCO purification was washed with diethyl ether to give the titlecompound as purple solid (100 mg, 61%). MS (ES+) m/z 357.0 [M+H]⁺ 1H NMR(400 MHz, DMSO-d6) δ ppm 13.76 (br. s., 1H), 7.95-8.06 (m, 1H), 7.91(dd, J=8.8, 2.3 Hz, 1H), 7.51-7.67 (m, 2H), 7.33-7.39 (m, 2H), 7.17-7.29(m, 1H), 4.85 (br s, 2H).

Example 2.6-(2-Fluorophenyl)-8-(trifluoromethyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxylicacid

Step 1: Diethyl2-[(2-chloroacetyl)amino]-2-[(E)-[2-(2-fluorobenzoyl)-4-(trifluoromethyl)phenyl]azo]propanedioate

To a stirring solution of[2-amino-5-(trifluoromethyl)phenyl]-(2-fluorophenyl)methanone (500 mg,1.77 mmol) in acetic acid (10 mL) at 0° C., hydrochloric acid(Concentrated) (0.44 mL, 5.3 mmol) was added. Sodium nitrite (0.35 mL,1.77 mmol) was also added. The solution was stirred at 0° C. for 15 min.Ice (0.4 g) was added. The solution of diethyl2-[(2-chloroacetyl)amino]propanedioate (444.28 mg, 1.77 mmol) in acetone(10 mL) was added dropwise quickly. Potassium carbonate (saturatedsolution) (0.6 mL, 1.77 mmol) was added. The pH of the solution wasbetween 5 and 6.5. The solution was stirred at room temperature for 1hour. The solution was extracted with ethyl acetate (2×20 ml). Thecombined organic solution was washed with water (1 ml) and brine (1 ml),dried over sodium sulfate. The solution was filtered and concentrated.The residue was purified by silica gel chromatography eluted with ethylacetate/hexane (0-50%) to give the title compound (0.9500 g) as deepcolored oil. MS (ES+) m/z 568.0 [M+Na]⁺. 1H NMR (CHLOROFORM-d) δ:7.77-7.88 (m, 2H), 7.56-7.71 (m, 1H), 7.29-7.35 (m, 1H), 7.09 (ddd,J=10.9, 8.3, 1.0 Hz, 3H), 4.23-4.40 (m, 4H), 4.10-4.17 (m, 1H), 3.88 (s,1H), 2.09-2.14 (m, 5H), 2.04-2.09 (m, 2H), 1.24-1.33 (m, 6H).

Step 2:5-(chloromethyl)-1-[2-(2-fluorobenzoyl)-4-(trifluoromethyl)phenyl]-1,2,4-triazole-3-carboxylicacid

To a stirring solution of diethyl2-[(2-chloroacetyl)amino]-2-[(E)-[2-(2-fluorobenzoyl)-4-(trifluoromethyl)phenyl]azo]propanedioate(0.76 g, 1.4 mmol) in methanol (40 mL), potassium carbonate (0.97 g, 7mmol) dissolved in water (5 mL) was added. The solution was stirred atroom temperature for 4 hrs. The solution was adjusted to acidic byadding hydrochloric acid (1.0 N, 20 ml). The solution was concentrated.The residue was dissolved in water (50 ml). The solution was extractedwith ethyl acetate (2×50 ml). The combined organic solution wasextracted with water (50 ml) and brine (50 ml), and dried over sodiumsulfate. The solution was filtered and concentrated to give the titlecompound (590 mg) as deep colored oil. MS (ES+) m/z 428.0 [M+H]⁺ 1H NMR(CHLOROFORM-d) δ: 8.00-8.08 (m, 2H), 7.87 (d, J=8.1 Hz, 1H), 7.65 (td,J=7.6, 1.8 Hz, 1H), 7.21-7.27 (m, 1H), 7.06 (dd, J=10.7, 8.5 Hz, 1H),4.71 (s, 2H)

Step 3:6-(2-Fluorophenyl)-8-(trifluoromethyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxylicacid

To a stirring solution of5-(chloromethyl)-1-[2-(2-fluorobenzoyl)-4-(trifluoromethyl)phenyl]-1,2,4-triazole-3-carboxylicacid (590 mg, 1.38 mmol) in ammonia methanol (11 mL, 77 mmol) mixture at0° C., potassium iodide (50 mg, 0.3000 mmol) was added. The solution wasstirred at room temperature for three days. The solution wasconcentrated. The residue was purified by preparative reverse-phasechromatography to give the title compound (34 mg) as white solid. MS(ES+) m/z 391.0 [M+H]⁺. 1H NMR (DMSO-d6) δ: 8.19-8.27 (m, 2H), 7.64-7.72(m, 2H), 7.54-7.62 (m, 1H), 7.36 (td, J=7.6, 1.0 Hz, 1H), 7.24 (dd,J=11.1, 8.3 Hz, 1H), 4.97 (br. s., 2H).

Example 3.8-Fluoro-6-(2-fluorophenyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxylicacid

Following the procedure for example 1 except starting with(2-amino-5-fluoro-phenyl)-(2-fluorophenyl)methanone afforded8-Fluoro-6-(2-fluorophenyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxylicacid as a solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.03 (dd, J=8.72, 4.93Hz, 1H) 7.71 (td, J=8.46, 2.78 Hz, 1H) 7.52-7.65 (m, 2H) 7.34 (td,J=7.3, 1.3 Hz, 1H) 7.23 (dd, J=8.3, 9.4 Hz, 1H); 7.18 (dd, J=9.1, 2.81H); 4.88 (br s, 2H).

Example 4.8-Bromo-6-(2-fluorophenyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxylicacid

Following the procedure for example 1 except starting with(2-amino-5-bromo-phenyl)-(2-fluorophenyl)methanone afforded8-Bromo-6-(2-fluorophenyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxylicacid as a solid. MS (ES+) m/z 400.9 [M+H, Br=81]⁺1H NMR (DMSO-d₆) δ:7.98-8.08 (m, 1H), 7.89-7.97 (m, 1H), 7.54-7.68 (m, 2H), 7.50 (d, J=2.0Hz, 1H), 7.31-7.41 (m, 1H), 7.19-7.31 (m, 1H), 4.92 (br. s., 1H).

Example 5.8-Chloro-6-(2,6-difluorophenyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxylicacid

Following the procedure for example 1 except starting with(2-amino-5-chloro-phenyl)-(2,6-difluorophenyl)methanone afforded8-chloro-6-(2,6-difluorophenyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxylicacid as a solid. MS (ES+) m/z 375 [M+H]⁺ ¹H NMR (DMSO-d₆) δ: 7.99-8.07(m, 1H), 7.92 (dd, J=8.7, 2.4 Hz, 1H), 7.55-7.66 (m, 1H), 7.47 (d, J=2.3Hz, 1H), 7.22 (t, J=8.5 Hz, 2H), 5.02 (s, 2H)

Example 6.8-chloro-6-(2-fluorophenyl)-N-(2-ureidoethyl)-4H-[1,2,4]triazolo[1,5-a][1,4]ben zodiazepine-2-carboxamide

To a stirring mixture of8-chloro-6-(2-fluorophenyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxylicacid (100 mg, 0.2800 mmol) and 2-aminoethylurea hydrochloride (58.69 mg,0.4200 mmol) in DMF (1.5 mL) was added N,N-diisopropylethylethylamine(108.68 mg, 0.8400 mmol) and HBTU (127.57 mg, 0.3400 mmol). The solutionwas stirred at room temperature for two days. The solution was directlypurified by reverse-phase preparative HPLC (C18 column, 150×20 mm I.D.,5 μm particle size, gradient elution 5% CH₃CN/H₂O w. 0.05% TFA modifierto 95% CH₃CN/H₂O w. 0.05% TFA modifier) to give the title compound aswhite solid. ¹H NMR (DMSO-d₆) δ: 8.76-8.83 (m, 4H), 8.02 (d, J=8.8 Hz,1H), 7.88-7.96 (m, 1H), 7.54-7.67 (m, 2H), 7.31-7.41 (m, 2H), 7.19-7.29(m, 1H), 3.97 (s, 2H), 3.25-3.35 (m, 2H), 3.17 (s, 4H).

Example 7.8-chloro-N-[2-(dimethylamino)ethyl]-6-(2-fluorophenyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxamide

Following the procedure for example 6 except starting with N,N-dimethylaminoethylamine afforded the title compound. MS (ES+) m/z 427.1 [M+H]⁺1H NMR (400 MHz, DMSO-d6) δ ppm: 9.34 (br. s., 1H), 8.98-9.08 (m, 1H),7.98-8.08 (m, 1H), 7.90-7.97 (m, 1H), 7.54-7.69 (m, 2H), 7.32-7.47 (m,2H), 7.19-7.30 (m, 1H), 4.94 (br. s., 2H), 3.63 (q, J=5.81 Hz, 2H), 3.28(d, J=5.81 Hz, 2H), 2.76-2.95 (m, 6H).

Example 8.2-[[8-chloro-6-(2-fluorophenyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carbonyl]amino]ethyl-trimethyl-ammoniumtrifluoroacetate

Following the procedure for example 6 except starting withN,N,N-trimethyl aminoethylammonium chloride afforded the title compound.MS (ES+) m/z 441.0 [M+]⁺1H NMR (400 MHz, DMSO-d6) δ ppm: 9.17 (t, J=5.94Hz, 1H), 8.69 (br. s., 1H), 7.98-8.07 (m, 1H), 7.90-7.97 (m, 1H),7.54-7.67 (m, 2H), 7.32-7.43 (m, 2H), 7.19-7.31 (m, 1H), 4.94 (br. s.,2H), 3.71 (d, J=6.57 Hz, 2H), 3.48-3.57 (m, 2H), 3.05-3.19 (m, 9H).

Example 9.8-chloro-6-(2-fluorophenyl)-N-[2-(sulfamoylamino)ethyl]-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxamide

Following the procedure for example 6 except starting with2-(sulfamoylamino)ethylamine afforded the title compound. MS (ES+) m/z513.1 [M+H]⁺ 1H NMR (400 MHz, DMSO-d6) δ ppm 1.13-1.26 (m, 7H) 1.99 (s,1H) 2.86-2.95 (m, 7H) 2.98-3.08 (m, 2H) 3.28-3.48 (m, 32H) 4.03 (q,J=7.07 Hz, 2H) 4.57 (s, 1H) 4.92 (br. s., 4H) 7.24 (dd, J=10.74, 8.46Hz, 3H) 7.31-7.42 (m, 7H) 7.53-7.68 (m, 2H) 7.89-7.96 (m, 3H) 7.98-8.08(m, 1H) 8.92 (q, J=5.64 Hz, 2H).

Example 10.N-(2-aminoethyl)-8-chloro-6-(2-fluorophenyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxamide

Following the procedure for example 6 except starting with excessethylenediamine afforded the title compound. ¹H NMR (400 MHz, DMSO-d6) δppm 2.67 (t, J=6.19 Hz, 2H) 3.26 (q, J=6.48 Hz, 16H) 4.92 (br. s., 9H)7.24 (dd, J=10.48, 8.46 Hz, 8H) 7.31-7.42 (m, 15H) 7.52-7.67 (m, 16H)7.88-7.96 (m, 7H) 7.99-8.09 (m, 8H) 8.69 (t, J=5.56 Hz, 6H).

Example 11.8-Chloro-6-(3-fluoro-2-pyridyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxylicacid

Step 1: Benzyl N-(2-chloro-2-oxo-ethyl)carbamate

To a stirring solution of Z-GLY-OH (5 g, 23.9 mmol) in dichloromethane(100 mL) at room temperature, oxalyl chloride (2.26 mL, 26.29 mmol) wasadded. DMF (three drops) was added afterward. The solution was stirredat room temperature for 5 hours. The solution was concentrated. Theresidue was used directly in the next reaction.

Step 2: Diethyl 2-[[2-(benzyloxycarbonylamino)acetyl]amino]propanedioate

To a stirring solution of benzyl N-(2-chloro-2-oxo-ethyl)carbamate (5.44g, 23.9 mmol) and diethyl-2-aminomalonate (5.0 g, 23.9 mmol) indichloromethane (100 mL) at 0° C., triethylamine (9.94 mL, 71.7 mmol)was added slowly into the solution. The solution was then heated underreflux for 20 min, then stirred at room temperature overnight.Dichloromethane (100 ml) was added. The solution was extracted withhydrochloric acid (1 N, 2×100 ml), water (100 mml, brine (100 ml), driedover sodium sulfate. The solution was filtered and concentrated. Theresidue was purified by silica gel chromatography eluted with ethylacetate/hexanes (0-70%) to give the title compound (5.392 g) as whitesolid. MS (ES+) m/z 367.1 [M+H]⁺. 1H NMR (CHLOROFORM-d) d: 7.30-7.41 (m,5H), 5.12-5.20 (m, 3H), 4.21-4.35 (m, 4H), 4.00 (d, J=5.6 Hz, 2H),1.26-1.36 (m, 6H).

Step 3: Diethyl2-[[2-(benzyloxycarbonylamino)acetyl]amino]-2-[(E)-[4-chloro-2-(3-fluoropyridine-2-carbonyl)phenyl]azo]propanedioate

To a stirring solution of(2-amino-5-chloro-phenyl)-(3-fluoro-2-pyridyl)methanone (500 mg, 1.99mmol) in acetic acid (10 mL) at room temperature, hydrochloric acid(Concentrated) (0.5 mL, 5.98 mmol) was added. Sodium nitrite (0.4 mL,1.99 mmol) was also added. The solution was stirred at room temperaturefor 15 min. Ice (1 g) was added. The solution was cooled in an ice-waterbath. The solution of diethyl2-[[2-(benzyloxycarbonylamino)acetyl]amino]propanedioate (730.81 mg,1.99 mmol) in acetone (20 mL) was added dropwise quickly. Potassiumcarbonate (saturated solution) (0.6 mL, 3.99 mmol) was added. The pH ofthe solution was between 5 and 6.5. The solution was stirred at roomtemperature for 45 min. The solution was extracted with ethyl acetate(2×50 ml). The combined organic solution was washed with water (1 ml)and brine (1 ml), dried over sodium sulfate. The solution was filteredand concentrated. The residue was purified by reverse phasechromatography (C18 column, linerar gradient 5% AcN to 95% AcN in 0.5%aqueous TFA) to give the title compound (383 mg) as colorless oil. MS(ES+) m/z 628.1 [M+H]⁺. 1H NMR (Chloroform-d) d: 8.37 (d, J=4.5 Hz, 1H),7.71 (d, J=8.6 Hz, 1H), 7.51-7.65 (m, 2H), 7.46 (d, J=3.5 Hz, 1H),7.31-7.41 (m, 4H), 5.52 (br. s., 1H), 5.17 (s, 2H), 4.18-4.36 (m, 4H),3.90 (d, J=5.6 Hz, 1H), 1.20-1.34 (m, 6H).

Step 4:5-(Benzyloxycarbonylaminomethyl)-1-4-chloro-2-(3-fluoropyridine-2-carbonyl)phenyl]-1,2,4-triazole-3-carboxylicacid

To a solution of diethyl2-[[2-(benzyloxycarbonylamino)acetyl]amino]-2-[(E)-[4-chloro-2-(3-fluoropyridine-2-carbonyl)phenyl]azo]propanedioate(203 mg, 0.3200 mmol) in THF (10 mL) and methanol (5 mL), potassiumcarbonate (0.2 mL, 1.29 mmol) was added. Water (2 mL) was addedafterwards. After one hour, ethyl acetate (50 ml) was added. Thesolution was washed with water (2×20 ml), brine (20 ml) and dried oversodium sulfate. The solution was filtered and concentrated to give thetitle compound (160 mg, 0.3138 mmol, 97.079% yield) as slightly coloredoil which was used directly in the next step without furtherpurification. MS (ES+) m/z 510.1 [M+H]⁺.

Step 5:8-Chloro-6-(3-fluoro-2-pyridyl)-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxylicacid

To a stirring solution of5-(benzyloxycarbonylaminomethyl)-1-[4-chloro-2-(3-fluoropyridine-2-carbonyl)phenyl]-1,2,4-triazole-3-carboxylicacid (170. mg, 0.3300 mmol) in acetic acid (3 mL), hydro bromic acid(1.5 mL, 48% 0.3300 mmol) was added. The solution was heated at 50° C.overnight. The solution was cooled to room temperature and directlypurified by reverse phase chromatography (C18 column, linerar gradient5% AcN to 95% AcN in 0.5% aqueous TFA) to give the title compound (106mg) as a solid. MS (ES+) m/z 358.0 [M+H]⁺. 1H NMR (DMSO-d6) d: 8.39 (dt,J=4.5, 1.4 Hz, 1H), 8.32 (s, 1H), 8.00 (d, J=8.8 Hz, 1H), 7.85-7.94 (m,2H), 7.61 (dt, J=8.7, 4.1 Hz, 1H), 7.50 (d, J=2.3 Hz, 1H), 5.00 (s, 2H).

Example 12.8-chloro-6-(2-fluorophenyl)-4H-imidazo[1,2-a][1,4]benzodiazepine-2-carboxylicacid

Step 1:7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepine-2-thione

7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one (10 g,34.64 mmol) and Lawesson's reagent (8.41 g, 20.78 mmol) in toluene (200ml) were stirred under reflux for 24 hours. The solution wasconcentrated. Dichloromethane (200 ml) was added. The solution wasextracted with water (2×100 ml), brine (100 ml), and dried over sodiumsulfate. The solution was filtered and concentrated. The residue waspurified by silica gel chromatography eluted with ethyl acetate/hexane(0-30%) to give the title compound (12.17 g) as a slightly coloredsolid. MS (ES+) m/z 305.0 [M+H]⁺. 1H NMR (CHLOROFORM-d) δ: 8.05-8.16 (m,1H), 7.58-7.67 (m, 1H), 7.45-7.54 (m, 2H), 7.21-7.31 (m, 2H), 7.16 (d,J=8.6 Hz, 1H), 6.99-7.12 (m, 2H), 4.81 (br. s., 6H), 3.87-3.93 (m, 2H).

Step 2:7-Chloro-5-(2-fluorophenyl)-2-methylsulfanyl-3H-1,4-benzodiazepine

7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepine-2-thione (12g, 35.44 mmol) was dissolved in ethanol (100 mL). The solution wascooled to 0° C., then sodium methoxide (1.43 g, 46.07 mmol) was added.The solution was stirred for 30 min., iodomethane (2.65 mL, 42.52 mmol)was added. The solution was stirred at room temperature overnight thenconcentrated. The residue was dissolved in ethyl acetate (200 ml) andextracted with water (2×50 ml) and brine (50 ml), then dried over sodiumsulfate. The solution was filtered and concentrated. The residue waspurified by silica gel chromatography eluted with ethyl acetate/hexane(0-30%) to give the title compound (7.62 g) as colorless oil. MS (ES+)m/z 319.0 [M+H]⁺. 1H NMR (CHLOROFORM-d) δ: 7.51-7.58 (m, 1H), 7.41-7.49(m, 2H), 7.30-7.35 (m, 1H), 7.18-7.27 (m, 2H), 7.05-7.13 (m, 1H), 2.52(s, 2H), 1.60 (s, 3H).

Step 3: Methyl2-[[7-chloro-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-yl]amino]-3-hydroxy-propanoate

To a stirring solution of7-chloro-5-(2-fluorophenyl)-2-methylsulfanyl-3H-1,4-benzodiazepine (1.47g, 4.61 mmol) in toluene (50 mL), L-serine methyl ester hydrochloride(2.15 g, 13.83 mmol), sodium acetate (1.51 g, 18.44 mmol) and aceticacid (0.05 mL, 4.61 mmol) were added. The solution was heated at 90° C.for two hours. The solution was concentrated. The residue was dissolvedin ethyl acetate (200 ml). The solution was extracted with water (100ml), brine (100 ml), dried over sodium sulfate. The solution wasfiltered and concentrated. The residue was purified by silica gelchromatography eluted with methanol/dichloromethane (0-15%) to give thetitle compound (330 mg) as slightly colored solid. MS (ES+) m/z 390.0[M+H]⁺. 1H NMR (DMSO-d6) δ: 8.11 (d, J=7.6 Hz, 1H), 7.46-7.64 (m, 2H),7.40 (dd, J=8.6, 2.5 Hz, 1H), 7.31 (td, J=7.6, 1.0 Hz, 1H), 7.24 (dd,J=10.6, 8.3 Hz, 1H), 7.03 (d, J=8.8 Hz, 1H), 6.95 (d, J=2.5 Hz, 1H),5.12 (t, J=5.6 Hz, 1H), 4.52 (br. s., 1H), 3.59-3.80 (m, 6H), 1.91 (s,2H).

Step 4: Methyl2-[[7-chloro-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-yl]amino]-3-oxo-propanoate

To a stirring solution of oxalyl chloride (0.26 mL, 2.98 mmol) indichloromethane (20 mL) at −78° C., dimethylsulfoxide (0.32 mL, 4.46mmol) was added. The solution was stirred at −78° C. for 40 min. Methyl2-[[7-chloro-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-yl]amino]-3-hydroxy-propanoate(580 mg, 1.49 mmol) in dichloromethane (20 mL) was added slowly into thesolution. The solution was stirred for another one hour at −78° C.Triethylamine (1.24 mL, 8.93 mmol) was added slowly into the solutionwith continued stirring at −78° C. for 30 min. and room temperature for30 min. Dichloromethane (20 ml) was added. The solution was washed withhydrochloric acid (1 N HCl, 2×20 ml), brine (1×30 ml), dried over sodiumsulfate. The solution was filtered and concentrated. The residue wasused directly in next step.

Step 5: Methyl8-chloro-6-(2-fluorophenyl)-4H-imidazo[1,2-a][1,4]benzodiazepine-2-carboxylate

To a stirring solution of methyl2-[[7-chloro-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-yl]amino]-3-oxo-propanoate(576.99 mg, 1.49 mmol) in toluene (20 mL), acetic anhydride (0.3 mL,5.95 mmol) was added. The solution was stirred at 110° C. for threehours. The solution was concentrated. The residue was purified by silicagel chromatography eluted with methanol/dichloromethane (0-10%) to givethe title compound (220 mg) as dark solid. MS (ES+) m/z 370.0 [M+H]⁺. 1HNMR (Chloroform-d) δ: 8.10 (s, 1H), 7.61-7.70 (m, 1H), 7.44-7.56 (m,2H), 7.33-7.38 (m, 1H), 7.20-7.26 (m, 1H), 7.01-7.09 (m, 1H), 5.32 (s,1H), 4.39 (s, 1H), 3.95 (s, 3H).

Step 6:8-chloro-6-(2-fluorophenyl)-4H-imidazo[1,2-a][1,4]benzodiazepine-2-carboxylicacid

To a stirring solution of methyl8-chloro-6-(2-fluorophenyl)-4H-imidazo[1,2-a][1,4]benzodiazepine-2-carboxylate(210 mg, 0.5700 mmol) in THF (5 mL) and methanol (5 mL), sodiumhydroxide (1.0 M, 1.42 mL, 1.42 mmol) was added. The solution wasstirred at room temperature for two hours. The solution was turned toacidic by adding hydrochloric acid (1.0 M). The solution wasconcentrated. The residue was dissolved in DMF (0.5 ml) and methanol(1.0 ml) and purified by reverse phase chromatography (C18 column,linear gradient 5% AcN to 95% AcN in 0.5% aqueous TFA) to give the titlecompound (52 mg) as slightly colored solid. MS (ES+) m/z 356.0 [M+H]⁺.1H NMR (DMSO-d6) δ: 8.55 (s, 1H), 8.32 (s, 1H), 7.91-7.96 (m, 1H), 7.84(dd, J=8.8, 2.5 Hz, 1H), 7.53-7.66 (m, 3H), 7.30-7.37 (m, 3H), 7.20-7.28(m, 1H).

The following exemplary compounds can be prepared by one skilled in theart using methods well-described in the literature. See also CH574426A5, CH 573931A5, DE2304307A1, DE2234620A1, DE2215943, DE2215943A1,DE2234620A1, DE2304307A1, DE2237592A1, U.S. Pat. Nos. 5,302,715,3,941,803, incorporated by reference herein in their entireties.

TABLE 1 Exemplary compounds of the present invention Number NameStructure Compound 13 8-chloro-6-(2-fluorophenyl)-4-hydroxy-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2- carboxylic acid

Compound 14 8-chloro-6-(2-fluorophenyl)-4H-imidazo[1,2-a][1,4]benzodiazepine-1-carboxylic acid

Compound 15 8-chloro-6-(2-fluorophenyl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-1- carboxylic acid

Compound 16 2-[5-(2-fluorophenyl)-2-oxo-7-(trifluoromethyl)-3H-1,4-benzodiazepin-1-yl]acetic acid

Compound 17 3-[7-chloro-5-(2-fluorophenyl)-2-oxo-3H-1,4-benzodiazepin-1-yl]propanoic acid

Example 13. Effects of the Compounds and Methods of the PresentInvention on Whole Gut Transit Time

Dose responses of the effect of Compound 1 on the whole gut transit time(WGTT) were examined. Compound 1 (0, 1, 3 and 10 mg/kg) in 50% propyleneglycol was administrated by gavage (5 ml/kg), followed by gavage of 0.2ml carmine red solution (6% carmine red in 0.5% methylcellulose) intoC57B/6 mice. Mice were then placed in a white cardboard box and the timewas recorded as time 0. The color of stool was observed every 10 minuntil the red dye appeared in stool. The time that first red stoolappears was recorded as the ending time. The difference between theending time and time 0 is used to present WGTT (min). As shown in FIG.1, Compound 1 dose-dependently increased WGTT with a statisticalsignificance at all 1, 3 and 10 mg/kg of Compound 1. These data suggestoral administration of Compound 1 slows the transition in thegastrointestinal system.

Example 14. Effects on Distal Colon Transit Time

We examined the time course of Compound 1 on distal colon transit time(DCTT) in C57B/6 mice to assess the colon motility. DCTT was performedby gently pushing a 2 mm glass bead into rectal 2 cm and then placingthe mouse into a white box (time 0). The time that the glass bead wasreleased from rectal is presented as DCTT (min). Mice were gavaged with0 or 3 mg/kg of Compound 1 and DTCC was conducted at 30, 60, 90 and 120min after the administration of Compound 1. Compound 1 (3 mg/kg)significantly increased the DCTT as early as 30 min after the gavage(FIG. 2). The increase in the DCTT reached a peak at 90 min and returnedat 2 hours after the administration of Compound 1 (FIG. 2). The resultssuggest that oral administration of Compound 1 reduces colon transition,which could be due to reduction of colon motility.

Example 15. Effects on Stool Composition

After gavage of Compound 1 (3 and 10 mg/kg), stools were collectedimmediately after expulsion for 3 hours. The wet stools were weighted astotal stool weight followed by dry at 65° C. for 24 hours and weight asdry stool weight. The percent of water content in the stool wascalculated by (total stool weight-dry stool weight)/total stoolweight×100. Treatment with 10 mg/kg, but not 3 mg/kg, of Compound 1significantly reduced the total stool weight and the percent of watercontent in the stool (FIG. 3). These data further suggest the reductionof transit, which is consistent with the results of WGTT and DCTT (FIGS.1 & 2).

Example 16. Pain Sensitivity in IBS Mouse Model

IBS visceral pain model, induced by neonatal rectal irritation. Colonicpain sensitivity to graded colorectal balloon distension (CRD, 15, 30,50 and 70 mmHg) was determined by visceromotor response (VMR) measuredby electromyography of external oblique muscle. IBS mice showed asignificant increase in pain sensitivity relative to control mice.Treatment with Compound 1 (10 mg/kg) significantly attenuated thehyperalgesia in IBS mice (Two-Way ANOVA, FIG. 4), whereas no effect wasobserved in control mice (data not shown). These data suggest Compound 1may be used to treat visceral pain.

Example 17. Measurement of Brain and Plasma Levels

Compound 1 was administered to 5 mice at a dose of 10 mg/kg as asolution in 50% propylene glycol by oral gavage (5 ml/kg), After 30minutes, mice were sacrificed and plasma and brain were harvested. Theconcentration of Compound 1 in plasma and brain were measured by LC/MS.Average plasma concentrations were 1061±189 nM, and brain concentrationwas lower than the limit of quantitation (62.5 nM).

Example 18. Measurement of GABA-A Binding

Potency at the GABA-A receptor can be measured by [³H]flunitrazepambinding to rat cerebral cortex tissue homogenate as described in Speth,R. C, Wastek, G. J., Johnson, P. C., Yamamura, H. I. “Benzodiazepinebinding in human brain: Characterization using [³H] flunitrazepam” LifeSciences 1978, 22, 859-866, and performed at CEREP (catalog number0028). Examples 1-12 have a Ki less than 500 nM.

The following references cited above are incorporate herein by referencein their entirety:

1. Everhart J E. The burden of digestive diseases in the United States.US Government Printing Office (NIH Publication No. 09-6443), 2008.

2. Sullivan M A, Cohen S, Snape W J, Jr. Colonic myoelectrical activityin irritable-bowel syndrome. Effect of eating and anticholinergics. NEngl J Med 1978; 298:878-83.

3. Gershon M D. Serotonin and its implication for the management ofirritable bowel syndrome. Rev Gastroenterol Disord 2003; 3 Suppl2:S25-34.

4. Pasricha P J. Desperately seeking serotonin. A commentary on thewithdrawal of tegaserod and the state of drug development for functionaland motility disorders. Gastroenterology 2007; 132:2287-90.

5. Fargeas M J, Fioramonti J, Bueno L. Central and peripheral action ofGABAA and GABAB agonists on small intestine motility in rats. EuropeanJournal of Pharmacology 1988; 150:163-169.

6. Grider J R. Interplay of somatostatin, opioid, and GABA neurons inthe regulation of the peristaltic reflex. American Journal ofPhysiology—Gastrointestinal and Liver Physiology 1994; 267:G696-G701.

7. Kerr D I B, Ong J. GABA and GABA-receptors in the enteric nervoussystem. Neuropharmacology 1984; 23:835-836.

8. Krantis A. GABA in the mammalian enteric nervous system. News inPhysiological Sciences 2000; 15:284-290.

9. Krantis A, Costa M, Furness J B, Orbach J. γ-Aminobutyric acidstimulates intrinsic inhibitory and excitatory nerves in the guinea-pigintestine. European Journal of Pharmacology 1980; 67:461-466.

10. Ong J, Kerr D I B. Evidence for a physiological role of GABA in thecontrol of guinea-pig intestinal motility. Neuroscience Letters 1984;50:339-343.

11. Reis H J, Berghe P V, Romano-Silva M A, Smith T K. GABA-inducedcalcium signaling in cultured enteric neurons is reinforced byactivation of cholinergic pathways. Neuroscience 2006; 139:485-494.

12. Williamson S, Faulkner-Jones B E, Cram D S, Furness J B, Harrison LC. Transcription and translation of two glutamate decarboxylase genes inthe ileum of rat, mouse and guinea pig. Journal of the Autonomic NervousSystem 1995; 55:18-28.

13. Williamson S, Pompolo S, Furness J B. GABA and nitric oxide synthaseimmunoreactivities are colocalized in a subset of inhibitory motorneurons of the guinea-pig small intestine. Cell and Tissue Research1996; 284:29-37.

14. Salari P, Abdollahi M. Systematic review of modulators ofbenzodiazepine receptors in irritable bowel syndrome: is there hope?World J Gastroenterol 2011; 17:4251-7.

15. Ritchie J A, Truelove S C. Treatment of irritable bowel syndromewith lorazepam, hyoscine butylbromide, and ispaghula husk. Br Med J1979; 1:376-8.

16. Pace F, Maurano A, Ciacci C, Savarino V, Attili A, Iaquinto G, MagniE, Porro G B. Octatropine methyl bromide and diazepam combination(Valpinax) in patients with irritable bowel syndrome: a multicentre,randomized, placebo-controlled trial. Eur Rev Med Pharmacol Sci 2010;14:155-62.

17. Talley N J. Evaluation of drug treatment in irritable bowelsyndrome. British Journal of Clinical Pharmacology 2003; 56:362-369.

18. Horvath K, Andrasi F, Berzsenyi P, Patfalusi M, Patthy M, Szabo G,Sebestyen L, Bagdy E, Korosi J, Botka P, Hamori T, Lang T. A NewPsychoactive 5h-2,3-Benzodiazepine with a Unique Spectrum of Activity.Arzneimittel-Forschung/Drug Research 1989; 39-2:894-899.

19. Mennini T, Abbiati A, Caccia S, Cotecchia S, Gomez A, Garattini S.Brain Levels of Tofizopam in the Rat and Relationship withBenzodiazepine Receptors. Naunyn-Schmiedebergs Archives of Pharmacology1982; 321:112-115.

20. Bagal S K, Bungay P J. Minimizing Drug Exposure in the CNS whileMaintaining Good Oral Absorption. Acs Medicinal Chemistry Letters 2012;3:948-950.

All references, including publications, patent applications, andpatents, cited herein are hereby incorporated by reference to the sameextent as if each reference were individually and specifically indicatedto be incorporated by reference and were set forth in its entiretyherein.

The use of the terms “a” and “an” and “the” and similar referents in thecontext of describing the invention (especially in the context of thefollowing claims) are to be construed to cover both the singular and theplural, unless otherwise indicated herein or clearly contradicted bycontext. The terms “comprising,” “having,” “including,” and “containing”are to be construed as open-ended terms (i.e., meaning “including, butnot limited to,”) unless otherwise noted. Recitation of ranges of valuesherein are merely intended to serve as a shorthand method of referringindividually to each separate value falling within the range, unlessotherwise indicated herein, and each separate value is incorporated intothe specification as if it were individually recited herein. All methodsdescribed herein can be performed in any suitable order unless otherwiseindicated herein or otherwise clearly contradicted by context. The useof any and all examples, or exemplary language (e.g., “such as”)provided herein, is intended merely to better illuminate the inventionand does not pose a limitation on the scope of the invention unlessotherwise claimed. No language in the specification should be construedas indicating any non-claimed element as essential to the practice ofthe invention.

Preferred embodiments of this invention are described herein, includingthe best mode known to the inventors for carrying out the invention.Variations of those preferred embodiments may become apparent to thoseof ordinary skill in the art upon reading the foregoing description. Theinventors expect skilled artisans to employ such variations asappropriate, and the inventors intend for the invention to be practicedotherwise than as specifically described herein. Accordingly, thisinvention includes all modifications and equivalents of the subjectmatter recited in the claims appended hereto as permitted by applicablelaw. Moreover, any combination of the above-described elements in allpossible variations thereof is encompassed by the invention unlessotherwise indicated herein or otherwise clearly contradicted by context.

The invention claimed is:
 1. A compound selected from the groupconsisting of:


2. A pharmaceutical composition comprising a compound of claim 1,wherein the compound is selected from the group consisting of:

and a pharmaceutically acceptable carrier.
 3. The pharmaceuticalcomposition of claim 2, further comprising at least one antibiotic agentselected from the group consisting of quinolone antibioticstrimethoprim-sulfamethoxazole antibiotics and combinations thereof.
 4. Amethod for the inhibition of gut motility in a subject comprisingadministering to the subject a pharmaceutical composition of claim
 2. 5.A method for treatment of irritable bowel syndrome in a subjectcomprising administering to the subject a pharmaceutical composition ofclaim
 2. 6. A method for treatment of functional abdominal pain,functional idiopathic diarrhea, inflammatory bowel diseases, druginduced pain, bile salt malabsorption, lactase or other carbohydrateintolerance in a subject comprising administering to the subject apharmaceutical composition of claim
 2. 7. A method for the inhibition ofgut motility in a subject comprising administering to the subject acompound of claim
 1. 8. A method for treatment of irritable bowelsyndrome in a subject comprising administering to the subject a compoundof claim
 1. 9. A method for treatment of functional abdominal pain,functional idiopathic diarrhea, inflammatory bowel diseases, druginduced pain, bile salt malabsorption, lactase or other carbohydrateintolerance in a subject comprising administering to the subject acompound of claim
 1. 10. A method for the inhibition of gut motility ina subject comprising administering to the subject a compound having thefollowing formula:


11. A method for treatment of irritable bowel syndrome in a subjectcomprising administering to the subject a compound having the followingformula:


12. A method for treatment of functional abdominal pain, functionalidiopathic diarrhea, inflammatory bowel diseases, drug induced pain,bile salt malabsorption, lactase or other carbohydrate intolerance in asubject comprising administering to the subject a compound having thefollowing formula: